From a cage to a model, from the heart to the brain : novel concepts in neuroprotection / Sarel Francois Malan

dc.contributor.author

Malan, Sarel Francois

dc.date.accessioned

2012-03-22T07:11:43Z

dc.date.available

2012-03-22T07:11:43Z

dc.date.issued

2005

dc.identifier.isbn

1868225097

dc.identifier.uri

http://hdl.handle.net/10394/6359

dc.description.abstract

Disorders like Parkinson's and Alzheimer's disease Neurodegenerative diseases, such as Parkinson's (PO) and Alzheimer's diseases, are
increasingly becoming a burden to society as the world's population is growing older.
Neurodegeneration and the development of neuroprotective agents have thus in recent
years become an increasingly important focus of research. Currently, relatively good
symptomatic therapy for PO exists, but no proven therapy that prevents cell death
(neuroprotection), or restores damaged neurons to a normal state (neurorescue) are
available. Intracellular calcium homeostasis, or rather the lack thereof, have in many
studies been implicated in neuronal degeneration and is currently believed to be one of
its main causes. An intracellular calcium overload leads to the activation of various
enzyme systems, as well as accumulation of free radicals intracellular. These and
other calcium related processes ultimately lead to cell death and neurodegeneration.
Previous studies evaluating the biological activity of the polycyclic cage amines indicate
activity that includes amongst others, neuroprotective activity and selectivity and high
affinity for the sigma-binding site. The pentacycloundecylamine derivatives show
structural similarities to known NMOA antagonists and its peripheral L-type calcium
channel antagonism as observed in cardiac myositis is well described. Although little is
known about the mechanisms of CNS activity of the compounds, it is postulated that
these derivatives could yet be of therapeutic value in the treatment of neurodegenerative.